Neoprobe Corporation Share Price Nyse
Equities
NEOP
US6405181065
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
21/06 | Navidea Biopharmaceuticals, Inc. Announces Board Resignations | CI |
2023 | Navidea Biopharmaceuticals, Inc. announced that it has received $0.75 million in funding | CI |
Sales 2021 | 5L 4.43Cr | Sales 2022 | 65.65T 54.72L | Capitalization | 67.78L 56Cr |
---|---|---|---|---|---|
Net income 2021 | -1.1Cr -92Cr | Net income 2022 | -1.5Cr -125.02Cr | EV / Sales 2021 | 50.2 x |
Net cash position 2021 | 34.81L 29Cr | Net Debt 2022 | 4L 3.67Cr | EV / Sales 2022 | 110 x |
P/E ratio 2021 |
-2.5
x | P/E ratio 2022 |
-0.38
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 64.11% |
Managers | Title | Age | Since |
---|---|---|---|
Craig Dais
DFI | Director of Finance/CFO | 58 | 28/23/28 |
Michael Blue
CTO | Chief Tech/Sci/R&D Officer | - | 01/21/01 |
Richard McFerron
LAW | General Counsel | - | 01/22/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Joshua Wilson
BRD | Director/Board Member | 47 | 30/22/30 |
John Scott
BRD | Director/Board Member | 69 | 08/21/08 |
Jill Stefanelli
BRD | Director/Board Member | 46 | 01/23/01 |
1st Jan change | Capi. | |
---|---|---|
+19.41% | 4.55TCr | |
-8.62% | 3.85TCr | |
+38.65% | 3.81TCr | |
+26.95% | 3.07TCr | |
-13.50% | 2.6TCr | |
+10.74% | 2.59TCr | |
+44.87% | 1.41TCr | |
+34.36% | 1.27TCr | |
-7.14% | 1.13TCr |
- Stock Market
- Equities
- NAVB Stock
- NEOP Stock